Surprisingly, migraine is in the 3rd place of all diseases occurring in the world and affects 12% of the population, between the ages of 25 and 55. Migraine headaches significantly affect the quality of human life, while limiting proper bio-psycho-social functioning. This explains the vigorous efforts of researchers to establish the still enigmatic pathomechanism of the disease. The dichotomy of migraine is based on its division into with aura or without aura, and its semiology is extremely diverse. Pharmacological and non-pharmacological treatment of migraines should include 2 strategies: immediate, aimed at combating the seizure, and prophylactic, the goal of which is to reduce the onset of the disease.

headache, migraine, aura, triptans

Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30;68(5):343-9.

GBD 2015: migraine is the third cause of disability in under 50s. Steiner TJ, Stovner LJ, Vos T. J Headache Pain.2016 Dec;17(1):104.

Dodick DW. Migraine. Lancet. 2018 Mar 31;391(10127):1315-1330.

Bille B.A 40-year follow-up of school children with migraine. Cephalalgia. 1997 Jun;17(4):488-91; discussion 487.

Linde M. Migraine: a review and future directions for treatment. Acta Neurol Scand. 2006 Aug;114(2):71-83.

Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010 May;30(5):599-609.

Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015 Mar;55 Suppl 2:103-22; quiz 123-6.

Buse DC, Scher AI, Dodick DW, Reed ML, Fanning KM, Manack Adams A, Lipton RB. Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. Mayo Clin Proc. 2016 Apr 25. pii: S0025-6196(16)00126-9.

Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain. 2016 Jul;139(Pt 7):1987-93.

Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014 Jan;137(Pt 1):232-41.

Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365-91.

Hadjikhani N, Sanchez Del Rio M, Wu O, Schwartz D, Bakker D, Fischl B, Kwong KK, Cutrer FM, Rosen BR, Tootell RB, Sorensen AG, Moskowitz MA. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4687-92.

Eikermann-Haerter K, Moskowitz MA. Animal models of migraine headache and aura. Curr Opin Neurol. 2008 Jun;21(3):294-300.

Hauge AW, Asghar MS, Schytz HW, Christensen K, Olesen J. Effects of tonabersat on migraine with aura: a randomised, double-blind, placebo-controlled crossover study. Lancet Neurol. 2009 Aug;8(8):718-23.

Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ. Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain. 2016 Jul;139(Pt 7):2002-14.

Ambrosini A, Kisialiou A, Coppola G, Finos L, Magis D, Pierelli F, Schoenen J. Visual and auditory cortical evoked potentials in interictal episodic migraine: An audit on 624 patients from three centres. Cephalalgia. 2017 Oct;37(12):1126-1134.

Brighina F, Palermo A, Fierro B. Cortical inhibition and habituation to evoked potentials: relevance for pathophysiology of migraine. J Headache Pain. 2009 Apr;10(2):77-84.

Noseda R, Jakubowski M, Kainz V, Borsook D, Burstein R. Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci. 2011 Oct 5;31(40):14204-17.

Bartsch T, Goadsby PJ The trigeminocervical complex and migraine: current concepts and synthesis. Curr Pain Headache Rep. 2003 Oct;7(5):371-6.

Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing.Physiol Rev. 2017 Apr;97(2):553-622.

International Headache Society. The international classification of headache disorders, 3rd edn. Cephalalgia 2018; 38: 1–211.

Gori S, Lucchesi C, Baldacci F, Bonuccelli U. Preferential occurrence of attacks during night sleep and/or upon awakening negatively affects migraine clinical presentation. Funct Neurol. 2015 Apr-Jun;30(2):119-23.

Kelman L. Pain characteristics of the acute migraine attack. Headache. 2006 Jun;46(6):942-53.

Friedman DI, Evans RW. Are Blurred Vision and Short-Duration Visual Phenomena Migraine Aura Symptoms? Headache. 2017 Apr;57(4):643-647.

Kelman L. The place of osmophobia and taste abnormalities in migraine classification: a tertiary care study of 1237 patients. Cephalalgia. 2004 Nov;24(11):940-6.

Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 2004 Jan;55(1):19-26

Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995;35(7):387-96.

Linde M, Mellberg A, Dahlöf C. The natural course of migraine attacks. A prospective analysis of untreated attacks compared with attacks treated with a triptan. Cephalalgia. 2006 Jun;26(6):712-21.

Nyka W, Bilińska M, Wójcik-Drączkowska H. Migrenna – rozpoznanie i leczenie. Forum Medycyny Rodzinnej 2007; 109-114.

Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet. 1995 Oct 7;346(8980):923-6.

Diener HC, Bussone G, de Liano H, Eikermann A, Englert R, Floeter T, Gallai V, Göbel H, Hartung E, Jimenez MD, Lange R, Manzoni GC, Mueller-Schwefe G, Nappi G, Pinessi L, Prat J, Puca FM, Titus F, Voelker M; EMSASI Study Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks.Cephalalgia. 2004 Nov;24(11):947-54.

The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur. Neurol. 1992; 32: 177–184. 89.

Geraud G, Compagnon A, Rossi A. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur. Neurol. 2002; 47: 88–98.

Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015 Jul-Aug;55 Suppl 4:221-35.

Stępień A. Kryteria diagnostyczne i leczenie migreny w oparciu o obowiązujące zalecenia międzynarodowe Rekomendacje Polskiego Towarzystwa Bólu Głowy dotyczące leczenia migreny. Medycyna po Dyplomie 2011(20); 9(186): 81-87.

Pringsheim T, Davenport W, Mackie G, Worthington I, Aubé M, Christie SN, Gladstone J, Becker WJ Canadian Headache Society Prophylactic Guidelines Development Group. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012 Mar;39(2 Suppl 2):S1-59.

Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol. 1993 Aug;50(8):825-30.

Linde M., Dahlöf C. Menstrual migraine: clinical considerations. Rev. Ser. Neurol. 2002; 4–8: 24.

Lemstra M, Stewart B, Olszynski WP. Effectiveness of Multidisciplinary Intervention in the Treatment of Migraine: A Randomized Clinical Trial; Volume42, Issue9 October 2002Pages 845-854.